Eckert & Ziegler: Strong Profit Growth in the Third Quarter
12 November 2002. Eckert & Ziegler AG, Berlin, a specialist for medical and industrial applications, succeeded in achieving one of the best quarterly results ever in the company's young history, with an operating income of nearly 1 million EUR (previous year: 0.6 Mio EUR). The result for the first nine months increased to about 1 Cent per share.
Sales revenues in the first nine months amounted to 23.8 Mio EUR (previous year: 24.7 Mio EUR). The Cardiology segment posted the biggest percentage increase in revenues surging 45% to 3.1 Mio EUR (previous year: 2.2 Mio EUR). Oncology increased by 11% to 4.7 Mio EUR (previous year: 4.3 Mio EUR) whereas the direct sales in Europe grew by 60%. Industry achieved 7.9 Mio EUR (previous year: 9.1 Mio EUR) and Nuclear Imaging 7.5 Mio EUR (previous year: 8.0 Mio EUR). The revenues of both segments suffered from the negative development in the USD exchange rate.
Strict cost controls in the Industry, Nuclear Imaging and Biotechnology segments represented an important contribution to the improved profit figures. On September 30, approximately 6.4 Mio EUR of cash, cash equivalents and short-term securities were available, around 2% more than at the same time last year. Due to higher biotechnology expenses and lower revenues from subsidies in the fourth quarter, the Board of Directors continues to expect a loss for the year, but now only of about 0.20 to 0.30 EUR per share. Sales revenues will be approximately 32 Mio EUR.
For further information please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations, http://www.ezag.com Tel.: +49 (0) 30 / 94 10 84-138 end of ad-hoc-announcement (c)DGAP 12.11.2002 --------------------------------------------------------------------------------
WKN: 565970; ISIN: DE0005659700; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 120730 Nov 02
Sales revenues in the first nine months amounted to 23.8 Mio EUR (previous year: 24.7 Mio EUR). The Cardiology segment posted the biggest percentage increase in revenues surging 45% to 3.1 Mio EUR (previous year: 2.2 Mio EUR). Oncology increased by 11% to 4.7 Mio EUR (previous year: 4.3 Mio EUR) whereas the direct sales in Europe grew by 60%. Industry achieved 7.9 Mio EUR (previous year: 9.1 Mio EUR) and Nuclear Imaging 7.5 Mio EUR (previous year: 8.0 Mio EUR). The revenues of both segments suffered from the negative development in the USD exchange rate.
Strict cost controls in the Industry, Nuclear Imaging and Biotechnology segments represented an important contribution to the improved profit figures. On September 30, approximately 6.4 Mio EUR of cash, cash equivalents and short-term securities were available, around 2% more than at the same time last year. Due to higher biotechnology expenses and lower revenues from subsidies in the fourth quarter, the Board of Directors continues to expect a loss for the year, but now only of about 0.20 to 0.30 EUR per share. Sales revenues will be approximately 32 Mio EUR.
For further information please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations, http://www.ezag.com Tel.: +49 (0) 30 / 94 10 84-138 end of ad-hoc-announcement (c)DGAP 12.11.2002 --------------------------------------------------------------------------------
WKN: 565970; ISIN: DE0005659700; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 120730 Nov 02